Yellow fever population is vaccinated. Control of the yellow fever mosquito "A. aegypti" is of major importance, especially because the same mosquito can also transmit dengue fever and chikungunya disease. "A. aegypti" breeds preferentially in water, for example in installations by inhabitants of areas with precarious drinking water supply, or in domestic waste, especially tires, cans, and plastic bottles. These conditions are common in urban areas in developing countries. Two main strategies are employed to reduce mosquito populations. One approach is to kill the developing larvae. Measures are taken to reduce the water accumulations in which the larvae develop. Larvicides are used,
Yellow fever culture the virus and won a Nobel Prize in 1951 for this achievement. A French team developed the French neurotropic vaccine (FNV), which was extracted from mouse brain tissue. Since this vaccine was associated with a higher incidence of encephalitis, FNV was not recommended after 1961. Vaccine 17D is still in use, and more than 400 million doses have been distributed. Little research has been done to develop new vaccines. Some researchers worry that the 60-year-old technology for vaccine production may be too slow to stop a major new yellow-fever epidemic. Newer vaccines, based on vero cells, are in development